LIPO 0.49 Lipella Pharmaceuticals Inc.
| Range: | 0.323-2.71 | Vol Avg: | 4233835 | Last Div: | 0 | Changes: | 0.04 |
| Beta: | 1.46 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Dec 19 2022 | Empoloyees: | 5 | ||
| CUSIP: | 53630L100 | CIK: | 0001347242 | ISIN: | US53630L1008 | Country: | US |
| CEO: | Dr. Jonathan Kaufman M.B.A., Ph.D. | Website: | https://www.lipella.com | ||||
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow